Transgenomic, Inc. Highlights Unique Advantages Of Multiplexed ICE COLD-PCR At Personalized Medicine World Conference

OMAHA, Neb. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ:TBIO) today announced that Ben Legendre, Jr., PhD, Vice President, Laboratory Operations, delivered a presentation yesterday at the Personalized Medicine World Conference. In his talk, Dr. Legendre highlighted how Transgenomic’s versatile and powerful Multiplexed ICE COLD-PCR™ (MX-ICP) technology enables personalized medicine R&D, exemplified by its utility for stratification of clinical study patients in partnership with Transgenomic’s pharmaceutical and biotechnology clients. In addition, the exceptional accuracy of MX-ICP and its ability to enable use of liquid biopsies are supporting the rapidly growing use of personalized and precision medicine strategies in routine clinical practice.